Nrx plans suicidal bipolar depression study despite phase IIIII trouble - BioWorld Online
| 1795 Stock | TWD 271.50 4.00 1.45% |
Slightly above 61% of Lotus Pharmaceutical's investor base is looking to short. The analysis of current outlook of investing in Lotus Pharmaceutical Co suggests that many traders are alarmed regarding Lotus Pharmaceutical's prospects. Lotus Pharmaceutical's investing sentiment can be driven by a variety of factors including economic data, Lotus Pharmaceutical's earnings reports, geopolitical events, and overall market trends.
Lotus Pharmaceutical stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Lotus daily returns and investor perception about the current price of Lotus Pharmaceutical Co as well as its diversification or hedging effects on your existing portfolios.
Lotus |
Nrx plans suicidal bipolar depression study despite phase IIIII trouble BioWorld Online
Read at news.google.com
 |
Lotus Pharmaceutical Fundamental Analysis
We analyze Lotus Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lotus Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lotus Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Lotus Pharmaceutical is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Lotus Pharmaceutical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lotus Pharmaceutical stock to make a market-neutral strategy. Peer analysis of Lotus Pharmaceutical could also be used in its relative valuation, which is a method of valuing Lotus Pharmaceutical by comparing valuation metrics with similar companies.
Peers
Lotus Pharmaceutical Related Equities
| 3443 | Global Unichip | 2.60 | ||||
| 8046 | Nan Ya | 2.47 | ||||
| 1513 | Chung Hsin | 1.30 | ||||
| 1760 | Panion BF | 1.54 | ||||
| 4142 | Adimmune Corp | 1.67 |
Additional Tools for Lotus Stock Analysis
When running Lotus Pharmaceutical's price analysis, check to measure Lotus Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Pharmaceutical is operating at the current time. Most of Lotus Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Lotus Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Pharmaceutical's price. Additionally, you may evaluate how the addition of Lotus Pharmaceutical to your portfolios can decrease your overall portfolio volatility.